<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208273</url>
  </required_header>
  <id_info>
    <org_study_id>CO-HO-RT/2004/31</org_study_id>
    <nct_id>NCT00208273</nct_id>
  </id_info>
  <brief_title>Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer</brief_title>
  <official_title>A Phase II Randomized Study to Compare Skin Late Toxicities of Concomitant Letrozole-Radiotherapy and Radiotherapy Followed by Letrozole as Adjuvant Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <brief_summary>
    <textblock>
      This trial will compare grade 2 or greater late skin toxicities of concomitant
      letrozole-radiotherapy and radiotherapy followed by letrozole as adjuvant therapy for
      postmenopausal women with receptor (estrogen receptor [ER] and/or progesterone receptor
      [PgR]) positive tumors. Each drug will be prescribed for 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is an open-label randomized multicenter phase II study.

      A ratio of 1 to 1 will be used for the randomization process between the two arms:

        -  Arm A : Letrozole 2.5 mg daily for 5 years started three weeks before the first day of
           adjuvant radiotherapy.

        -  Arm B : Letrozole 2.5 mg daily for 5 years started three weeks after the last day of
           adjuvant radiotherapy.

      All patients will be followed every 3 months for toxicities, disease status and for survival
      until death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sub-cutaneous late toxicity</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung late toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic results</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole - Concomitant</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole - Sequential</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Compliant postmenopausal women

          -  Conservative breast cancer surgery

          -  Extension evaluation of disease will be proven negative

          -  Patients with tumor negative margins

          -  Patients will be classified as T1, T2, T3; Sentinel node negative, N0, N1 or N2; M0.

          -  Receptor positive tumors (ER and/or PgR = 10 fmol/mg cytosol protein; or = 10% of the
             tumor cells positive by immunocytochemical evaluation).

          -  Adequate marrow function (polynuclear neutrophils &gt;= 1200.10^9/l, platelets &gt;=
             100.10^9/l, and hemoglobin &gt;= 10 g/dl).

          -  Hepatic function (bilirubin &gt;= 30 µmol/l, ALT (SGPT) or AST (SGOT) &gt;= 1.5 x upper
             limit of the institution) and cholesterol level &lt;2 x upper limit of the institution.

          -  Must be geographically accessible for follow-up.

          -  Written and dated informed consent

        Exclusion Criteria:

          -  Patients with distant metastases.

          -  Bilateral breast cancer (concomitant or prior) except in situ lesion, either ductal or
             lobular, of the contralateral breast.

          -  Patients staged T4 or N3 or treated by not conservative surgery (radical mastectomy).

          -  Patients with neoadjuvant chemotherapy or hormonal therapy.

          -  Patients with previous or concomitant other (not breast cancer) malignancy within the
             past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or
             in situ carcinoma of the cervix. Patients who have had a previous other malignancy
             must have been disease free for at least five years.

          -  Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic,
             lung embolism, etc.) which would prevent prolonged follow-up.

          -  Patients treated with systemic investigational drugs within the past 30 days.

          -  Breast cancer chemoprevention with anti-estrogens

          -  Hormone replacement therapy (HRT) not stopped at least 4 weeks before randomization

          -  Patients known to be HIV positive (no specific tests are required to determine the
             eligibility).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David AZRIA, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRLC Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Azria D, Pelegrin A, Dubois JB, Mirimanoff RO, Ozsahin M. Radiation therapy and tamoxifen: concurrent or sequential? It's no longer the question! J Clin Oncol. 2005 Jun 20;23(18):4239-41; author reply 4241-2.</citation>
    <PMID>15961779</PMID>
  </reference>
  <reference>
    <citation>Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res. 2005;7(1):R156-63. Epub 2004 Dec 7.</citation>
    <PMID>15642164</PMID>
  </reference>
  <reference>
    <citation>Azria D, Gourgou S, Sozzi WJ, Zouhair A, Mirimanoff RO, Kramar A, Lemanski C, Dubois JB, Romieu G, Pelegrin A, Ozsahin M. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer. 2004 Oct 4;91(7):1251-60.</citation>
    <PMID>15328527</PMID>
  </reference>
  <reference>
    <citation>Azria D, Lemanski C, Zouhair A, Gutowski M, Belkacémi Y, Dubois JB, Romieu G, Ozsahin M. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art]. Cancer Radiother. 2004 Jun;8(3):188-96. Review. French.</citation>
    <PMID>15217586</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 13, 2007</last_update_submitted>
  <last_update_submitted_qc>December 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2007</last_update_posted>
  <keyword>Postmenopausal breast cancer, radiohormonotherapy sequences</keyword>
  <keyword>ER+ and/or PgR+,</keyword>
  <keyword>Postmenopausal Breast cancer,</keyword>
  <keyword>Adjuvant setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

